ARTICLES BY LOUIS

• A Real Dissertation On Tech Transfer

  10/10/2020

  A biopharma professional is earning a degree in tech transfer. Literally. Here’s some of what he’s learned, including the four thorns in the side of those transferring drug development and manufacturing projects to CDMOs.

• Outsourcing Trend Of The Year? The CDMO Synergy Sprint

  10/4/2020

  Two more CDMOs – this time in Germany – announce their best-in-breed alliance. What are these partnerships all about? Will this trend benefit readers looking for the best outsourcing outcomes? 

• Hello From The Other Side: Advice On Drug Development Outsourcing

  10/1/2020

  Some colleagues worked at CDMOs before joining your biopharma organization. Given the opportunity, they can guide you to enlightened vendor management and improved outsourcing outcomes.

• Today's Biotech Start-Up: Experienced Leaders, Wise Investors

  9/27/2020

  Biopharma start-ups and their investors have grown up. “They come in with a different mindset,” says Sesha Neervannan, Tarsus Pharmaceuticals, still enthusiastic about his own career move from bigger pharma to biotech.

• CDMOs Should Take On More Project Ownership

  9/17/2020

  "I want to hire CDMOs that take shared accountability and more ownership of the projects, products, and of the relationship," says a biopharma executive. You should, too. Here's how.

• Wanted: Multi-Experienced Employees For Outsourcing

  9/11/2020

  Jana Spes of Ironwood Pharmaceuticals provides uniquely qualified analysis and guidance on working with CDMOs. Don’t be surprised if you come away thinking for your next hire, specialization is out, and the Spes model is in.

• 2 Years For Vaccine Tech Transfers? COVID-19 Won't Wait

  9/2/2020

  A McKinsey & Company report, “Why tech transfer may be critical to beating COVID-19,” indicates the typical time to tech transfer a new vaccine is 27-29 months. Over 2 years for a tech transfer? Experts say yes. But not for COVID-19.

• 2 CDMOs Better Than All-In-One: The “Best-In-Breed” Trend

  8/31/2020

  We’ve uncovered a global trend in drug development and manufacturing outsourcing. I spoke to senior executives at four service providers to learn the trend is part antidote – and potentially a better option – to the “one-stop-shop” composite.

• Is PhRMA's White House Rebuttal Acceptable?

  8/24/2020

  While the biopharmaceutical industry can only be commended for the work underway to bring the world vaccines and therapies to halt the spread and severity of COVID-19, it would be ironic if PhRMA uses the pandemic as leverage to maintain the drug supply-chain status quo.

• Shedding Light On Outsourcing Shadows

  8/18/2020

  A new report sheds some light on biotech and pharma contract service agreements (CSAs) with CDMOs. Despite remaining shadows, it reveals less multiservice relationships and more large-molecule announcements than we might have expected.